– EpiVax joins Intravacc and CEPI in the project to develop a universal vaccine against betacoronavirus
PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce its participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines against betacoronaviruses, including SARS-CoV-2. EpiVax will carry out the part of the collaboration related to the selection of vaccine epitopes using the iVAX link.”
This program is funded in the link to accelerate the development of broadly protective vaccines against coronaviruses, which will provide up to $200 million for such projects. link”, which is designed for intranasal administration to provide protective immunity to multiple betacoronaviruses, including SARS-CoV-1, SARS-CoV-2, and MERS-CoV. Avacc 101 uses the link to deliver the payload usefulness of the vaccine and achieve an effective immune response.
As a co-founder of the project, EpiVax will identify cross-reactive beta-coronavirus T-cell epitopes for broad coverage of the class 1 and class 2 HLA-restricted epitopes of COVID-19, MERS, and SARS, using the link. In addition to vaccine epitope selection, EpiVax will also develop multiple designs and validate these constructs in silico in vivo with HLA transgenic mice.
According to Dr. Annie De Groot, CEO and Chief Scientific Officer of EpiVax, “We truly appreciate the opportunity to apply our advanced vaccine design tools to a problem of global importance.”
About EpiVax:
EpiVax is a biotechnology company with expertise in T-cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax’s Immunogenicity Screening Toolkits for Therapeutics and Vaccines, ISPRI and iVAX, are used to advance research for a global list of companies. For more information, visit www.epivax.com.
About Intravacc:
Intravacc is a world leading contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. Intravacc has transferred its technology related to polio, measles, DPT, Hib and influenza vaccines around the world. Intravacc offers extensive experience in developing vaccines from concept through Phase I/II clinical studies for academic, industry and philanthropic partners. For more information, visit www.intravacc.nl.
Press contact:
Katie Porter, Associate Director, Business Development and MarketingEpiVaxkporter@epivax.com
Emisor: EpiVax, Inc.
logo – link
View original content: enlace
